ProCE Banner Activity

My Take on Key Studies on axSpA and axPsA Presented at EULAR 2021

Conference Coverage
Clinical Thought
Expert faculty commentary on key studies of axSpA and axPsA presented at EULAR 2021 and their impact on clinical management.

Released: August 10, 2021

Expiration: August 09, 2022

Share

Faculty

Philip Mease

Philip Mease, MD, MACR

Director, Rheumatology Research
Providence Swedish Medical Center
Clinical Professor
University of Washington School of Medicine
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Janssen administered by Scientific Affairs

Faculty Disclosure

Primary Author

Philip Mease, MD, MACR

Director, Rheumatology Research
Providence Swedish Medical Center
Clinical Professor
University of Washington School of Medicine
Seattle, Washington

Philip Mease, MD, MACR, has disclosed that he has received consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; funds for research from AbbVie, Amgen, Bristol-Myers Squibb, Galapagos, Gilead Sciences, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and fees for non-CME/CE services from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB.